BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22399503)

  • 1. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.
    Kumar S; Iyer S; Bauer H; Coenen M; Bahn RS
    J Clin Endocrinol Metab; 2012 May; 97(5):1681-7. PubMed ID: 22399503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.
    Turcu AF; Kumar S; Neumann S; Coenen M; Iyer S; Chiriboga P; Gershengorn MC; Bahn RS
    J Clin Endocrinol Metab; 2013 May; 98(5):2153-9. PubMed ID: 23482611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
    Kumar S; Coenen M; Iyer S; Bahn RS
    Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.
    Kumar S; Schiefer R; Coenen MJ; Bahn RS
    Thyroid; 2010 Jan; 20(1):59-65. PubMed ID: 20017620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy.
    Kumar S; Nadeem S; Stan MN; Coenen M; Bahn RS
    J Mol Endocrinol; 2011 Jun; 46(3):155-63. PubMed ID: 21321093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro.
    Place RF; Krieger CC; Neumann S; Gershengorn MC
    Br J Pharmacol; 2017 Feb; 174(4):328-340. PubMed ID: 27987211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
    Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; Abel BS; Skarulis MC; Kahaly GJ; Neumann S; Gershengorn MC
    J Clin Endocrinol Metab; 2016 Jun; 101(6):2340-7. PubMed ID: 27043163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.
    Krieger CC; Neumann S; Place RF; Marcus-Samuels B; Gershengorn MC
    J Clin Endocrinol Metab; 2015 Mar; 100(3):1071-7. PubMed ID: 25485727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
    van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
    Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.
    van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects and Its Mechanism of IGF-1R on the Synthesis of Hyaluronic Acid in Orbital Fibroblasts of Thyroid Associated Ophthalmopathy].
    Chen XL; He WM; Li W
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Sep; 48(5):727-731. PubMed ID: 29130665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyrotropin Receptor Antagonism by a Novel Small Molecule: Preclinical
    Kahaly GJ; Steiner L; van der Lee MMC; van Achterberg TAE; Arends RJ; Karstens WFJ; Weirauch T; Henseling J; Frommer L; Wolf J; George A
    Thyroid; 2023 Jun; 33(6):732-742. PubMed ID: 37016815
    [No Abstract]   [Full Text] [Related]  

  • 13. TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.
    Chen H; Shan SJ; Mester T; Wei YH; Douglas RS
    PLoS One; 2015; 10(6):e0130322. PubMed ID: 26087256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
    Dik WA; Virakul S; van Steensel L
    Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
    van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
    Thyroid; 2011 Feb; 21(2):169-76. PubMed ID: 20954819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy.
    Zhang L; Grennan-Jones F; Lane C; Rees DA; Dayan CM; Ludgate M
    J Clin Endocrinol Metab; 2012 Feb; 97(2):653-62. PubMed ID: 22162480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
    Wiersinga WM
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 19. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy.
    Zhang L; Grennan-Jones F; Draman MS; Lane C; Morris D; Dayan CM; Tee AR; Ludgate M
    J Clin Endocrinol Metab; 2014 Jul; 99(7):E1183-90. PubMed ID: 24758182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
    Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.